Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 225

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 7
Chunk 225
---
 Ended December 31,

    2024

    2023

    2022

    Net loss attributable to Adaptive Biotechnologies Corporation
     
    $
    (159,492
    )
     
    $
    (225,250
    )
     
    $
    (200,191
    )

    Interest and other income, net

    (14,534
    )

    (15,531
    )

    (4,056
    )

    Interest expense(1)

    11,580

    13,800

    4,238

    Depreciation and amortization expense

    19,256

    22,231

    20,920

    Impairment of long-lived assets(2)

    7,205

    25,429

    —

    Restructuring expense(3)

    2,004

    —

    2,023

    Share-based compensation expense(4)

    53,610

    62,908

    55,477

    Adjusted EBITDA
     
    $
    (80,371
    )
     
    $
    (116,413
    )
     
    $
    (121,589
    )

(1) Represents costs associated with our revenue interest liability and noncash interest costs associated with the amortization of the related deferred issuance costs. See Note 11, Revenue Interest Purchase Agreement of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for details on the Purchase Agreement.

(2) Represents impairment costs for certain long-lived assets. See Note 10, Leases and Note 15, Restructurings of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for details on our impairment expense.

(3) Represents personnel-related expenses recognized in conjunction with restructuring activities. See Note 15, Restructurings of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for details on our restructuring expense.

(4) Represents share-based compensation expense related to stock option, restricted stock unit and market-based restricted stock unit awards. See Note 14, Equity Incentive Plans of the accompanying notes to the consolidated financial statements included elsewhere in this Annual Report on Form 10-K for details on our share-based compensation expense.

Liquidity and Capital Resources

We have incurred losses since inception and